The Market for Biopharmaceuticals was Worth USD 101 Billion in 2010

Noida, India (PressExposure) August 01, 2011 -- The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. IMARC Group, one of the world's leading research and advisory firms, in its new report entitled "Global Biopharmaceutical Market Report (2010-2015)" finds that more than three hundred biopharmaceuticals have already been approved and many more are in late stage clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases, but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry's USD 101 Billion figures and double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get approval represent goldmines for investors.

Key Aspects Analyzed in This Report:

Evaluating the Critical Success and Risk Factors Operating in the Global Biopharmaceutical Market:

Focus of the analysis:

• An Insight on the Key Strengths of the Global Biopharmaceutical Market

• An Insight on the Key Weaknesses of the Global Biopharmaceutical Market

• Evaluating the Key Opportunities for the Global Biopharmaceutical Market

• Evaluating the Key Threats faced by the Global Biopharmaceutical Market

Comprehensive Situation Analysis of the Global Biopharmaceutical Market:

Focus of the analysis:

• Evaluating the Historical, Current and Future Market Performance

• Evaluating The Historical, Current and Future Market Performance by Region

• Evaluating The Historical, Current and Future Market Performance by Biological Class

• Evaluating the Market Performance by Indication

• Evaluating the Performance of Major Biopharmaceutical Manufacturers

• Evaluating the Performance of Major Biopharmaceutical Brands

An In-depth Analysis of Various Developed and Emerging Biopharmaceutical Markets:

Countries Covered: US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey, Mexico, South Korea, India, Brazil, Argentina and Indonesia.

Biological Classes Covered for Each Country: Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins, Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors, Monoclonal Antibodies and Purified Proteins.

Focus of the analysis in each country:

• Evaluating the Historical, Current and Future Market Performance

• Evaluating the Performance by Biological Classes

• Evaluating the Performance of Major Biopharmaceutical Manufacturers

Table of Contents:

1. Market Definitions & Research Methodology

2. Analyst Briefing

3. Introduction to Biopharmaceuticals

4. Global Biopharmaceutical Market: Industry Analysis

4.1 Strengths

4.1.1 High Efficacy and Target Oriented Attack

4.1.2 Strong Potential to Achieve Blockbuster Status

4.1.3 Limited Generic Threat

4.1.4 Approval Success Rates are Higher than Small Molecule Drugs

4.2 Weaknesses

4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives

4.2.2 Second Line of Therapy

4.2.3 Huge Cost of Therapy

4.2.4 High Incidence of Unfavorable Side Effects

4.3 Opportunities

4.3.1 Diseases with High Unmet Needs

4.3.2 Expanding the Patient Pool by Approval into Additional Indications

4.3.3 Emerging Markets

4.3.4 Increasing New Approvals and a Strong Pipeline

4.4 Threats

4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture

4.4.2 Biosimilars

4.4.3 Limited and Conditional Reimbursement

4.4.4 Uncertainties in the Economic Environment

5. Global Biopharmaceutical Market: Industry Performance

5.1 Market Performance & Forecast

5.1.1 Current Performance (2005-2009)

5.1.2 Market Forecasts (2010-2015)

5.2 Market Segmentation by Region

5.2.1 Current Performance (2005-2009)

5.2.2 Market Forecasts (2010-2015)

5.3 Market Segmentation by Indication

5.4 Market Segmentation by Class

5.4.1 Recombinant Proteins

5.4.1.1 Current Performance (2005-2009)

5.4.1.2 Market Forecasts (2010-2015)

5.4.2 Monoclonal Antibodies

5.4.2.1 Current Performance (2005-2009)

5.4.2.2 Market Forecast (2010-2015)

5.4.3 Purified Proteins

5.4.3.1 Current Performance (2005-2009)

5.4.3.2 Market Forecast (2010-2015)

5.5 Competitive Landscape

5.5.1 Top Biopharmaceutical Players

5.5.2 Top Biopharmaceutical Drugs

6. North America

6.1 US

6.1.1 Market Performance (2005-2009)

6.1.2 Market Segmentation by Class

6.1.2.1 Recombinant Proteins

6.1.2.2 Monoclonal Antibodies

6.1.2.3 Purified Proteins

6.1.3 Performance of Top Players

6.1.4 Market Forecasts (2010-2015)

6.2 Canada

6.2.1 Market Performance (2005-2009)

6.2.2 Market Segmentation by Class

6.2.2.1 Recombinant Proteins

6.2.2.2 Monoclonal Antibodies

6.2.3 Performance of Top Players

6.2.4 Market Forecasts (2010-2015)

7. Latin America

7.1 Mexico

7.1.1 Market Performance (2005-2009)

7.1.2 Market Segmentation by Class

7.1.2.1 Recombinant Proteins

7.1.2.2 Monoclonal Antibodies

7.1.2.3 Purified Proteins

7.1.3 Performance of Top Players

7.1.4 Market Forecasts (2010-2015)

7.2 Brazil

7.2.1 Market Performance (2005-2009)

7.2.2 Market Segmentation by Class

7.2.2.1 Recombinant Proteins

7.2.2.2 Monoclonal Antibodies

7.2.2.3 Purified Proteins

7.2.3 Performance of Top Players

7.2.4 Market Forecasts (2010-2015)

7.3 Argentina

7.3.1 Market Performance (2005-2009)

7.3.2 Market Segmentation by Class

7.3.2.1 Recombinant Proteins

7.3.2.2 Monoclonal Antibodies

7.3.2.3 Purified Proteins

7.3.3 Performance of Top Players

7.3.4 Market Forecasts (2010-2015)

8. Europe

8.1 Germany

8.1.1 Market Performance (2005-2009)

8.1.2 Market Segmentation by Class

8.1.2.1 Recombinant Proteins

8.1.2.2 Monoclonal Antibodies

8.1.2.3 Purified Proteins

8.1.3 Performance of Top Players

8.1.4 Market Forecasts (2010-2015)

8.2 France

8.2.1 Market Performance (2005-2009)

8.2.2 Market Segmentation by Class

8.2.2.1 Recombinant Proteins

8.2.2.2 Monoclonal Antibodies

8.2.2.3 Purified Proteins

8.2.3 Performance of Top Players

8.2.4 Market Forecasts (2010-2015)

8.3 Italy

8.3.1 Market Performance (2005-2009)

8.3.2 Market Segmentation by Class

8.3.2.1 Recombinant Proteins

8.3.2.2 Monoclonal Antibodies

8.3.2.3 Purified Proteins

8.3.3 Performance of Top Players

8.3.4 Market Forecasts (2010-2015)

8.4 Spain

8.4.1 Market Performance (2005-2009)

8.4.2 Market Segmentation by Class

8.4.2.1 Recombinant Proteins

8.4.2.2 Monoclonal Antibodies

8.4.2.3 Purified Proteins

8.4.3 Performance of Top Players

8.4.4 Market Forecasts (2010-2015)

8.5 UK

8.5.1 Market Performance (2005-2009)

8.5.2 Market Segmentation by Class

8.5.2.1 Recombinant Proteins

8.5.2.2 Monoclonal Antibodies

8.5.2.3 Purified Proteins

8.5.3 Performance of Top Players

8.5.4 Market Forecasts (2010-2015)

8.6 Russia

8.6.1 Market Performance (2005-2009)

8.6.2 Market Segmentation by Class

8.6.2.1 Recombinant Proteins

8.6.2.2 Monoclonal Antibodies

8.6.2.3 Purified Proteins

8.6.3 Performance of Top Players

8.6.4 Market Forecasts (2010-2015)

8.7 Turkey

8.7.1 Market Performance (2005-2009)

8.7.2 Market Segmentation by Class

8.7.2.1 Recombinant Proteins

8.7.2.2 Monoclonal Antibodies

8.7.2.3 Purified Proteins

8.7.3 Performance of Top Players

8.7.4 Market Forecasts (2010-2015)

9. Asia Pacific

9.1 Japan

9.1.1 Market Performance (2005-2009)

9.1.2 Market Segmentation by Class

9.1.2.1 Recombinant Proteins

9.1.2.2 Monoclonal Antibodies

9.1.2.3 Purified Proteins

9.1.3 Performance of Top Players

9.1.4 Market Forecasts (2010-2015)

9.2 China

9.2.1 Market Performance (2005-2009)

9.2.2 Market Segmentation by Class

9.2.2.1 Recombinant Proteins

9.2.2.2 Monoclonal Antibodies

9.2.2.3 Purified Proteins

9.2.3 Performance of Top Players

9.2.4 Market Forecasts (2010-2015)

9.3 Australia

9.3.1 Market Performance (2005-2009)

9.3.2 Market Segmentation by Class

9.3.2.1 Recombinant Proteins

9.3.2.2 Monoclonal Antibodies

9.3.2.3 Purified Proteins

9.3.3 Performance of Top Players

9.3.4 Market Forecasts (2010-2015)

9.4 South Korea

9.4.1 Market Performance (2005-2009)

9.4.2 Market Segmentation by Class

9.4.2.1 Recombinant Proteins

9.4.2.2 Monoclonal Antibodies

9.4.2.3 Purified Proteins

9.4.3 Performance of Top Players

9.4.4 Market Forecasts (2010-2015)

9.5 India

9.5.1 Market Performance (2005-2009)

9.5.2 Market Segmentation by Class

9.5.2.1 Recombinant Proteins

9.5.2.2 Monoclonal Antibodies

9.5.2.3 Purified Proteins

9.5.3 Performance of Top Players

9.5.4 Market Forecasts (2010-2015)

9.6 Indonesia

9.6.1 Market Performance (2005-2009)

9.6.2 Market Segmentation by Class

9.6.2.1 Recombinant Proteins

9.6.2.2 Monoclonal Antibodies

9.6.2.3 Purified Proteins

9.6.3 Performance of Top Players

9.6.4 Market Forecasts (2010-2015)

To buy the complete report or to get a free sample:

Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)

Email: sales@imarcgroup.com

For more information please visit: http://www.imarcgroup.com/global-biopharmaceutical-market-report-2010-2015/

About IMARC Group

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Press Release Source: http://PressExposure.com/PR/IMARC_Group.html

Press Release Submitted On: August 01, 2011 at 5:06 am
This article has been viewed 23041 time(s).